Stockholm, March 3, 2022 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the first global patient treatment with its next-generation IRRAflow system, the company’s lead product that uses active fluid exchange to treat patients with intracranial bleeding.
Dr. Nicholas Brandmeir, a neurosurgeon from the Rockefeller Neuroscience Institute at West Virginia University and WVU Medicine Ruby Memorial Hospital (WVUH), successfully treated the first global patient suffering from a hemorrhagic stroke with the next-generation IRRAflow system.
“Over the last year, our team has been utilizing IRRAflow’s active fluid exchange technology to therapeutically treat our hemorrhagic stroke patients,” said Dr. Brandmeir. “We are excited to have the opportunity to be the first in the world to be able to utilize the next-generation IRRAflow system. The new IRRAflow control unit has welcomed improvements from a procedural workflow standpoint, which will benefit our team and patients.”
“The first patient treatment with our next-generation IRRAflow system is a critical next step in our company’s accelerating commercial launch,” said Will Martin, President and Chief Executive Officer of IRRAS. “Dr. Nicholas Brandmeir and the team at WVUH have been wonderful partners as we jointly work to transform how critically ill patients with intracranial bleeding are treated and provide them and their families hope for improved outcomes from this debilitating disease.”
Earlier last month, the surgeons from WVUH presented clinical data from the hospital’s treatment of its first 45 patients using the IRRAflow system across multiple intracranial pathologies. The data presented demonstrated that the use of IRRAflow resulted in a 0% catheter occlusion rate, a decreased percentage of observed vasospasm, and a reduced need for shunt placement after treatment. All of WVUH’s published data compared favorably to historic published rates.
The presentation can be viewed at the following link: https://youtu.be/GsNeYLvUuk8
The IRRAflow system offers an advanced approach to fluid management by actively exchanging intracranial fluids through recurring irrigation that dilutes collected toxic material, making it easier to remove, and prevents solid particles from blocking drainage holes, ensuring that fluid can continuously be drained throughout the entire treatment. In clinical data that has been published to date, IRRAflow’s combination of automated irrigation and controlled drainage has been shown to result in fewer complications, more thorough drainage, and reduced required treatment time.
This next-generation IRRAflow control unit will serve as the foundation of IRRAS’ commercial efforts moving forward. The system has been enhanced based on early user feedback and will improve the overall user experience with:
- Step-by-step interactive tutorials to guide system setup,
- Additional data tracking to help nursing better assess the patient’s condition each hour of treatment,
- An intuitive graphical user interface that simplifies treatment workflow and adjustment of treatment parameters, and
- A new drainage collection design that provides additional options to optimize fluid drainage.
Click here to experience the next-generation IRRAflow system.
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Director, Investor Relations
+46 102 11 5172
The information was released for public disclosure, through the agency of the contact person above, on March 3, 2022, at 8:00 (CET).